According to a study presented today at the 30th Symposium EORTC-NCI-AACR on molecular targets and cancer therapeutics, a new drug designed to enhance the effectiveness of radiation therapy was found to be safe.
The advantage of the drug, called ropidoksiuridinom (IPdR), lies in the fact that patients can take it in capsule form rather than intravenously. When the drug is ingested, it is converted to its active form, which makes the cancer cells more susceptible to the effects of radiation therapy.
Results of the study US NCI № 9882 presented by Dr. Timothy Kinsella of the department of radiation oncology at the Medical School of Brown University Warren Alpert and hospitals in Rhode Island in the United States, show that the drug has minimal side effects.
"Previous studies have shown that a promising compound called yodedeoksiuridinom or IUdR, works very well to enhance the effectiveness of radiation therapy, but IUdR can be administered only intravenously, and he had a lot of side effects. As a result, a new drug IPdR, which can be taken in capsule form has been developed. Inside the body it is converted into an active drug IUdR », - said Dr. Kinsella.
Dr. Kinsella and his colleagues tested a new drug in a group of 18 patients with advanced cancer. In addition to radiotherapy, patients received a daily dose IPdR within 28 days. The researchers examined levels of both IPdR, and IUdR active drug.
Results of the study show that IPdR can be safely administered to patients in an amount of 1200 mg per day for 28 days without causing serious side effects. The results also indicate that this dose produces IUdR levels of active drug in the blood of patients.
Among the patients, some had a complete response (disappearance of the tumor), three showed partial response (tumor shrinkage by at least 30%), nine were stable state (no tumor growth), and one patient discontinued treatment due to an infection and progressive disease (for at least 20% of tumor growth).
"Clinical studies have shown that when patients take IPdR home before the session of radiotherapy, IUdR levels in their blood stream is high enough to make the treatment more effective. At this dose IPdR, required to reach therapeutic levels in the blood IUdR, causing minimal side effects, - said Kinsella. - However, this study was conducted in patients with recurrent cancer who had previously tried other treatments. In the case of new patients can safely use a higher dose, providing a greater effect on the tumor. "
Dr. Kinsella and his colleagues have studied the effects of IPdR in patients undergoing radiation therapy for cancer that has spread to the brain. Professor Eric Deutsch, professor of radiation oncology and director of radiation oncology and research unit at the Institute Gustave Roussy, Vilyuif, France, said: "Radiotherapy is an essential element in the treatment of many forms of cancer. This study shows whether the drug can IPdR make therapy more effective for more patients. In the treatment of cancer patients, we must always take into account the risks and benefits of any treatment. In this study, the risks IPdR the drug were minimal, and the advantage is that patients can take the drug at home. "